相关实验视频

Updated: Jun 14, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

RET 变化差异化甲状腺髓癌的分子概况

Kumar Prabhash^1,2, Elveera Saldanha^1,3,4, Vijay Patil^1,2

¹Homi Bhabha National Institute (HBNI), Mumbai, India.

JCO precision oncology

|May 16, 2024

概括

这项研究详细介绍了印度队列中甲状腺髓癌 (MTC) 的基因组景观,确定了新的RET突变和超出已知的生物标志物的潜在治疗标.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
分子生物学分子生物学

背景情况:

骨髓甲状腺癌 (MTC) 源自甲状腺C细胞,RET突变很常见.
现有的研究往往侧重于已知的生物标志物,在理解多样化的MTC基因组资料方面留下了差距.

研究的目的:

在印度队伍中对甲状腺髓癌进行深入的基因组表征.
为了识别超出已建立的RET,KRAS和BRAF变化的新型治疗生物标志物.

主要方法:

32个MTC组织样本的整体全外和全转录组测序.
对突变景观,分子途径和瘤免疫微环境的分析.
使用分子对接和动态的新型RET突变的结构特征.

主要成果:

在50%的病例中发现了RET突变,在RET阴性队列中发现了KRAS,HRAS,SF3B1和BRAF中的其他突变.
途径分析显示,在RET-阴性MTC病例中,转录放松调节基因中的突变得到了丰富.
一种新的RET酶域突变,Y900S,对RET抑制剂表现出亲和力.

结论:

提供了对印度MTC患者的全面基因组见解.
表明MTC中有针对性治疗的潜力,特别是在RET阴性病例中.
强调先进测序对于发现新型治疗策略的重要性.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...